Erratum: Synthesis of 99mTc-DOTMP and Its Preclinical Evaluation as a Multidentate Imaging Agent for Skeletal Metastases (Cancer Biotherapy and Radiopharmaceuticals (2009) 24:1 (123-128) DOI: 10.1089/cbr.2008.0536);Synthesis of 99mTc-DOTMP and its preclinical evaluation as a multidentate imaging agent for skeletal metastases

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 1, 2009, Pages 123-128

  Datta, Anupama ^a   Panwar, Puja ^a   Chuttani, Krishna ^a   Mishra, Anil Kumar ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

99mTc; Bone imaging; DOTMP

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE TETRAMETHYLENEPHOSPHONIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAKIS(METHYLENEPHOSPHONIC ACID); 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAKIS(METHYLENEPHOSPHONIC ACID); CHELATING AGENT; ORGANOPHOSPHORUS COMPOUND; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SCREENING; DRUG SYNTHESIS; DRUG TUMOR LEVEL; GAMMA IRRADIATION; IMAGE ANALYSIS; ISOTOPE LABELING; LD 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; CHEMISTRY; METASTASIS; METHODOLOGY; RAT; SCINTISCANNING; SYNTHESIS; TIME; TISSUE DISTRIBUTION;

ANIMALS; BONE NEOPLASMS; CHELATING AGENTS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; ORGANOPHOSPHORUS COMPOUNDS; RABBITS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RATS; TECHNETIUM; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 60849137233     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2008.0536.correx     Document Type: Erratum

References (26)

1. 89Sr-therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: A preliminary report. J Urol 1976;116:764.
2. Hendrikson FR, Sheinkop MB. Management of osseous metastasis. Semin Oncol 1975;2:399.
3. Blomen LJMJ. In: Bijvoet OLM, Fleish RE, Canfield RE, etal., eds. Bisphosphonates on Bones. Amsterdam, The Netherlands: Elsevier Science Publishers, B.V., 1990:11.
4. Francis MD, Ferguson DL, Tofe AJ, et al. Comparative evaluation of three diphosphanates' in vitro adsorption (C-14 labeled) and in vitro osteogenic uptake (Tc-99m complexed). J Nucl Med 1980;21:1185.
5. Richards AG. Metastatic calcification detected through scanning with Tc-99m polyphosphate. J Nucl Med 1974;15:1057.
6. Rodan GA, Fleisj HA. Bisphosphonates: Mechanisms of action. J Clin Invest 1996;12:2692.
7. 99mTc-HDP for the detection of bone metastases. Eur J Nucl Med 1983;8:118.
8. 99mTc-MDP agents. Eur J Nucl Med 1983;8:395.
9. Maxon HR, Deutsch EA, Thomas SR, et al. Re-186 (Sn)-HEDP for treatment of multiple metastatic foci in bone: Human biodistribution and dosimetric studies. Radiology 1988;166:501.
10. Val J, Lewington BM. Bone-seeking radionuclides for therapy. J Nucl Med 2005;46:38S.
11. Turner JH, Martindale AA, Charmaine de Witt G, et al. Samarium-153 chelate localization in malignant malenoma. Eur J Nucl Med 1987;13:432.
12. Goeckler WF, Edwards B, Volkert WA, et al. Skeletal localization of samarium-153 chelates: Potential therapeutic bone agents. J Nucl Med 1987;28,495.
13. Volkert WA, Hofmann TJ. Therapeutic radiopharmaceuticals. Chem Rev 1999;99:2269.
14. Chilton HM, Francis MD, Thrall JH. In: Swanson DP, Chilton HM, Thrall JH, eds. Pharmaceuticals in Medical Imaging, New York: Macmillan, 1990:537.
15. Liang X, Sadler PJ. Cyclam complexes and their application in medicine. Chem Soc Rev 2004;3:246.
16. 186Re-1,4,8,11- tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: A novel agent for possible use in metastatic bone-pain palliation. Nucl Med Bio 2001;28:709.
17. 212Bi-DOTMP: An alpha-particle-emitting bone-seeking agent for targeted radiotherapy. Nucl Med Bio 1997;24:231.
18. 99mTc] human serum albumin. Nucl Med Bio 2001;28:425.
19. Banerjee S, Pillai MRA, Natesan R. Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin Nucl Med 2001;4:260.
20. Hamdy NA, Papapoulos SE. The palliative management of skeletal metastases in prostate cancer: Use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med 2001;31:62.
21. Fitton A, McTavish D. Pamidrdronate. A review of its pharmacological properties and therapeutic efficacy in responsive bone disease. Drugs 1991;41:289.
22. Bisaz S, Jung A, Fleish H. Uptake by bone of pyrophosphate, diphosphonate, and their technetium derivatives. Clin Sci Mol Med 1978;54:265.
23. Moedritzer K, Irani R. The direct synthesis of a-aminomethylene phosphonic acids: Mannich-type reaction with orthophosphorous acid. J Org Chem 1966;31:1603.
24. Bailya T, Burgada R, Lecouvey M, et al. Racemic trans-1,2- diaminocyclohexane as a template in the synthesis of ligands for transition metal and actinide in vivo detoxification. Phosphorus Sulfur Silicon 1995;101:131.
25. 99mTc for the detection of skeletal metastases. Nucl Med Commun 2006;27:619.
26. 99mTc-based multidentate phosphonate chelate: 5-amino-1,3-bis(ethylamine-(N,N dimethyl diphosphonic acid) acetamido) benzene. Bio Med Chem 2007;15:1138.